NCT06944847 Vaping and Smoking Project in People With Schizophrenia
| NCT ID | NCT06944847 |
| Status | Recruiting |
| Phase | — |
| Sponsor | State University of New York at Buffalo |
| Condition | Acute Abstinence From Cigarettes vs E-cigarettes (ENDS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2025-02-15 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 64 participants in total. It began in 2025-02-15 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed research will characterize withdrawal among people with schizophrenia who vape daily compared to people with schizophrenia who smoke combustible cigarettes daily, filling critical gaps in the understanding of electronic nicotine delivery systems (ENDS) dependence and contributing to the development of vaping cessation interventions amongst people with schizophrenia, the leading preventable cause of death in the US.
Eligibility Criteria
Inclusion Criteria: * 6+ months of daily/near-daily nicotine vaping or cigarette smoking * 200+ ng/mL cotinine on a commercially-available quick screen * stable antipsychotic medication dose (no changes in past 6 months). Current Exclusion Criteria: * intention to quit daily/near-daily vaping/smoking in the next month * current (2+ days out of the past 7) use of pipe tobacco, hookah/shisha, smokeless tobacco, dissolvable tobacco, nicotine pouches. For vaping group only, current (2+ days out of past 7) use of cigars, cigarillos, or filtered cigars that are filled with tobacco or a mix of tobacco and marijuana * current use of any smoking cessation medication * current severe substance dependence other than tobacco/nicotine (including cannabis; NIDA Modified ASSIST of 27+) * current (past 2 weeks) suicidal ideation with intent and/or plan * pregnancy (intake urine screen) * florid psychosis or severe cognitive symptoms (score of ≥5 on PANSS items delusions (P1), hallucinatory behavior (P3), or unusual thought content (G9), conceptual disorganization (P2), abstract thinking (N5), or poor attention (G11) or a score ≥6 on grandiosity (P5) or suspiciousness (P6)
Contact & Investigator
Larry Hawk, PhD
PRINCIPAL INVESTIGATOR
University at Buffalo
Frequently Asked Questions
Who can join the NCT06944847 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 50 Years, studying Acute Abstinence From Cigarettes vs E-cigarettes (ENDS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06944847 currently recruiting?
Yes, NCT06944847 is actively recruiting participants. Contact the research team at lhawk@buffalo.edu for enrollment information.
Where is the NCT06944847 trial being conducted?
This trial is being conducted at Buffalo, United States.
Who is sponsoring the NCT06944847 clinical trial?
NCT06944847 is sponsored by State University of New York at Buffalo. The principal investigator is Larry Hawk, PhD at University at Buffalo. The trial plans to enroll 64 participants.